Commentary|Videos|March 12, 2025
Data From an Age-Related Subgroup Analysis of the ARASENS Trial in mHSPC
Author(s)Daniel J. George, MD, Matthew Smith, MD, PhD
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.
Leonard J. Appleman, MD, PhD, discusses prior data with SYNC-T Therapy SV-102 and the ongoing LEGION-100 study in prostate cancer.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
lan M. Thompson Jr, MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.
Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
3
Pooled Analysis Reveals Strong Pirtobrutinib Efficacy in Frontline CLL
4
Lutetium Lu 177 Vipivotide Tetraxetan Approval Reshapes the Treatment Landscape for PSMA+ mHSPC
5